TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05993585

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Test Of The Frank Starling Mechanism - Adjustment Of Av Delay And Measurement Of Pre-load -Control
Description: (Control Group): One test of the Starling mechanism Visit 1: Sign consent form, doctor assessment, electrocardiogram (ECG), Starling Test. If patients are in this category, this will be their only research visit

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Other: Test Of The Frank Starling Mechanism - Adjustment Of Av Delay And Measurement Of Pre-load -CRT
Description: (CRT Group): Two tests of the Starling mechanisms Visit 1: Sign consent form, assessment by doctor, electrocardiogram (ECG), Test of the Starling mechanism Visit 2: CRT upgrade procedure - your Cardiologist will explain this procedure to you. Visit 3: CRT pacing check at 6 weeks post-procedure Visit 4: Assessment by doctor, ECG, Echocardiogram, Test of the Starling mechanism at 6 months post-procedure.
Study: NCT04741867

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Education
Description: Patients will be educated to determine their level of coping with stress and their adaptation.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Education
Description: Patients will be educated to determine their level of coping with stress and their adaptation.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Education
Description: Patients will be educated to determine their level of coping with stress and their adaptation.
Study: NCT04670042

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SPRINT® Peripheral Nerve Stimulation (PNS) System (510k Cleared)
Description: Same as Arm Description.
Study: NCT04952116

Intervention type: OTHER
Group type: OTHER
Intervention: Eyelid reconstruction
Description: Assessment of differrent techniques in anterior and posterior lamella reconstruction after periocular defects
Study: NCT05869526

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Fish oil
Description: EPA rich fish oil

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Kril oil
Description: Superba Krill Oil

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Vegetable oil
Description: Mixed vegetable oil
Study: NCT06246019

Intervention type: DIAGNOSTIC_TEST
Intervention: Early adoption of blood-based biomarkers for Alzheimer's disease
Description: A blood test will be performed to obtain plasma measures of Amyloid-β (Aβ) 42/40, phosphorylated tau (p-tau) 181, p-tau217, p-tau231 and Glial fibrillary acidic protein (GFAP) and Neurofilament light chain (NfL) and results will be disclosure to the early and late arms at different time points.

Intervention type: DIAGNOSTIC_TEST
Intervention: Early adoption of blood-based biomarkers for Alzheimer's disease
Description: A blood test will be performed to obtain plasma measures of Amyloid-β (Aβ) 42/40, phosphorylated tau (p-tau) 181, p-tau217, p-tau231 and Glial fibrillary acidic protein (GFAP) and Neurofilament light chain (NfL) and results will be disclosure to the early and late arms at different time points.
Study: NCT06332664

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Early Nutrition Intervention
Description: This involves a multidisciplinary team intervention, including oncologists, nutritionists, and nurses. Additionally, the intervention introduces a team-developed mobile application (APP) for the purpose of regular patient follow-ups to identify nutritional risks promptly and facilitate timely interventions. Patients identified as at risk through the app follow-up will be referred to the nutrition clinic for consultation to address nutritional concerns. For advanced-stage cancer patients undergoing monthly chemotherapy hospitalizations, comprehensive assessments encompassing nutrition, psychological aspects, and other facets will be conducted during hospital stays. When deemed necessary, patients will receive dietary guidance and nutritional support.
Study: NCT05192018

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Early reversal of a defunctiong ileostomy
Description: Early reversal of a defunctiong ileostomy after 3 weeks of its creation

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Early reversal of a defunctiong ileostomy
Description: Early reversal of a defunctiong ileostomy after 3 weeks of its creation
Study: NCT05154617

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Standard surgical monitoring, along with the Flo Trac® system monitoring.
Description: Under standard thoracic anesthesia protocol, extra monitoring will be done by FloTrac® System using a minimally invasive sensor in combination with an advanced monitoring device to derive cardiac output (CO) and cardiac index (CI) parameters through arterial pulse pressure waveform analysis. Intraoperative blood gases collection will be at different intraoperative times. From this data, calculations will be performed to obtain DO2, DO2i, O2ER, and O2ERi.
Study: NCT05166382

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Informed of results from SomaSignal Cardiovascular Risk Test in Type 2 Diabetes (CVD-T2D)
Description: Providers and patients will be informed of CVD-T2D test results that predict the risk of cardiovascular events over the next 4 years after their first research visit.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Not informed of results from SomaSignal Cardiovascular Risk Test in Type 2 Diabetes (CVD-T2D)
Description: Providers and patients will be informed of CVD-T2D test results that predict the risk of cardiovascular events over the next 4 years after their second research visit.
Study: NCT06337474

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: anti-CD19 CAR NK cells (KN5501)
Description: Patients will receive Fludarabine (25 mg/m2 per day) and Cyclophosphamide (1000mg/m2 per day) on day -3. Doses of 9×10\^9 cells, 13.5×10\^9 anti-CD19 CAR NK cells (KN5501) will infused in each group using the dose-escalation strategy
Study: NCT05986968

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ticagrelor
Description: Ticagrelor monotherapy for 12 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Description: Ticagrelor monotherapy for 12 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin
Description: Dual antiplatelet therapy (aspirin plus ticagrelor) for 12 months
Study: NCT04881929

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KN026
Description: KN026 in Combination With Docetaxel
Study: NCT04243902

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fill and Flush Valve
Description: The fill and flush valve (Figure 1) is an automated valve which is designed to open in response to rising bladder pressure which occurs as the bladder becomes full. The valve is situated between the IDC and the drainage bag as a manual valve would be.~There are three variants of the valve which respond to different degrees of bladder pressure. People's bladders function at different pressure levels. One of the aims of this study is to gain preliminary data on which valve variant works and under which circumstances. Pressure ranges are as follows:~Low: 22 - 49cm H2O Medium: 35 - 61cm H2O High: 53 - 79cm H2O
Study: NCT06296407

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard metabolic integrated rehabilitation protocol + respiratory exercises - duration 3 weeks
Description: Standard metabolic integrated rehabilitation protocol + respiratory exercises (12 sessions \[5 sessions/week for 3 weeks\])
Study: NCT05173441

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Human COVID-19 immunoglobulin (pH4) for intravenous injection
Description: The initial infusion rate is 0.01 \~ 0.02 ml/kg body weight/minute (1ml is about 20 drops). If there was no adverse reaction after 15 minutes, the infusion rate could be gradually accelerated. However, it should not exceed 0.08 ml/kg body weight/minute.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Human COVID-19 immunoglobulin (pH4) for intravenous injection
Description: The initial infusion rate is 0.01 \~ 0.02 ml/kg body weight/minute (1ml is about 20 drops). If there was no adverse reaction after 15 minutes, the infusion rate could be gradually accelerated. However, it should not exceed 0.08 ml/kg body weight/minute.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The initial infusion rate is 0.01 \~ 0.02 ml/kg body weight/minute (1ml is about 20 drops). If there was no adverse reaction after 15 minutes, the infusion rate could be gradually accelerated. However, it should not exceed 0.08 ml/kg body weight/minute
Study: NCT04648696

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vancomycin CI
Description: The CI group will have their total daily cumulative dose of vancomycin converted to a 24-hour intravenous infusion upon discharge - the CI will begin with the first scheduled OPAT dose of vancomycin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vancomycin II
Description: Study candidates that are randomized to the II group will continue their current intravenous dosing upon discharge
Study: NCT05189834

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Gelsectan
Description: Xyloglucan, vegetable protein and xylooligosaccharides

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Gelsectan
Description: Xyloglucan, vegetable protein and xylooligosaccharides
Study: NCT05768204

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisolone Acetate
Description: The experimental group took prednisolone acetate which is a kind of oral glucocorticoid.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: A placebo consistent in appearance with the prednisolone acetate.
Study: NCT05446792

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: PFMT
Description: The PFMT will consist of 10 maximum voluntary contractions that must be maintained for at least 6 seconds. Participants will be encouraged to sustain the maximum contraction for a longer time each week. The interval time between contractions will be the same seconds as the contraction. Participants will perform 4 sets of 10 contractions, and at the end of each set of 10 contractions, five fast contractions will be performed. Each series will be performed in one position: lying in lateral decubitus; seated; on all fours and standing.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PE
Description: The PE group will be instructed and reminded to voluntarily contract the PFMs during each repetition of the Pilates strengthening exercises. During the stretching exercises, the participant will be instructed not to perform the contraction.~The stretching and strengthening exercises will be performed in a single series of 10 repetitions, totaling 10 exercises aimed at the main muscle groups.
Study: NCT05179603

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: THOR-707
Description: Pharmaceutical Form: Solution for infusion Route of Administration: Intravenous infusion
Study: NCT05671211

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Task-Oriented Training
Description: Participants in this group will receive 30 minutes of task-oriented training and 1 hour of conventional therapy for 6 weeks 5 times a week.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Therapy
Description: Conventional therapy will be consisted of balance,upper and lower extremity strengthening exercises.
Study: NCT05533450

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Multi-focal rigid scleral contact lens
Description: True scleral lenses rest on the sclera and do not touch the cornea and limbus, leaving a clear area between the contact lens and the cornea.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Rigid gas permeable contact lens
Description: RGP contact lens is designed from a special rigid hydrophobic material. Patients wear RGP contact lens to form a contact lens-tear-cornea system to correct irregular astigmatism, reduce aberrations, provide good visual quality, and control the development of the disease through mild shaping effect.
Study: NCT05985018

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Traditional Diet
Description: Provided as an educational leaflet
Study: NCT06159959

Intervention type: DRUG
Intervention: Carbetocin
Description: To assess the effectiveness of single IV bolus dose of carbetocin in the prevention of primary PPH in obese versus non obese women undergoing elective cesarean section.

Intervention type: DRUG
Intervention: Carbetocin
Description: To assess the effectiveness of single IV bolus dose of carbetocin in the prevention of primary PPH in obese versus non obese women undergoing elective cesarean section.
Study: NCT06397196

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laser guided proprioceptive exercises
Description: Participants will receive Laser guided Proprioceptive exercises on alternate days (3 days a week) for 3 weeks. Total number of sessions will be 9

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Routine Physical therapy
Description: Participants will receive routine physical therapy on alternate days (3 days a week) for 3 weeks. Total number of sessions will be 9

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Routine Physical therapy
Description: Participants will receive routine physical therapy on alternate days (3 days a week) for 3 weeks. Total number of sessions will be 9
Study: NCT05698225

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Streptococcus pneumoniae serotype 6B
Description: A controlled concentration of streptococcus pneumoniae serotype 6B is placed in both nares of participants
Study: NCT05179603

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: THOR-707
Description: Pharmaceutical Form: Solution for infusion Route of Administration: Intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pharmaceutical Form: Solution for infusion Route of Administration: Intravenous infusion
Study: NCT06052826

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Best Practice
Description: Undergo standard of care

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cognitive Intervention
Description: Receive delirium prevention education

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Comprehensive Geriatric Assessment
Description: Undergo geriatric assessment

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nutritional Intervention
Description: Undergo nutritional optimization

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Physical Therapy
Description: Undergo physical function optimization

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT05985018

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Mediterranean Diet
Description: Provided as an educational leaflet
Study: NCT06133790

Intervention type: GENETIC
Intervention: PCR - Immunohistochemistry - Immunolabelling
Description: Genetic analysis will be conducted on biopsy to define molecular profile of head and neck tumors
Study: NCT04685707

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Visual feedback monitoring system (HFFS)
Description: Participants will follow the exercise monitoring system's instructions displayed on a TV. Treadmill walking speed will be set at a comfortable walking speed.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Visual feedback monitoring system (HFFS)
Description: Participants will follow the exercise monitoring system's instructions displayed on a TV. Treadmill walking speed will be set at a comfortable walking speed.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control
Description: Participants will monitor the intensity of exercise independently using a standard heart rate monitor and control it by adjusting the treadmill speed (walking speed).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control
Description: Participants will monitor the intensity of exercise independently using a standard heart rate monitor and control it by adjusting the treadmill speed (walking speed).
Study: NCT06533644

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SV-102
Description: SV-102 will be administered as an intratumoral infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SV-102
Description: SV-102 will be administered as an intratumoral infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SV-102
Description: SV-102 will be administered as an intratumoral infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SV-102
Description: SV-102 will be administered as an intratumoral infusion.
Study: NCT06024421

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: favipiravir
Description: Light yellow, film-coated tablet, each containing 200 mg of favipiravir

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: favipiravir
Description: Light yellow, film-coated tablet, each containing 200 mg of favipiravir

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: favipiravir
Description: Light yellow, film-coated tablet, each containing 200 mg of favipiravir

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Light yellow, film-coated tablet

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Light yellow, film-coated tablet

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Light yellow, film-coated tablet
Study: NCT04729569

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Feather edge finish line preparation
Description: Tooth preparation with feather edge finish line will be done to posterior teeth to receive all ceramic full coverage zirconia crowns.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Deep chamfer finish line preparation
Description: Tooth preparation with deep chamfer finish line will be done to posterior teeth to receive all ceramic full coverage zirconia crowns.
Study: NCT05193799

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Investigational devices must be used 8 hours per day
Description: During 3 consecutive days

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Investigational devices must be used 8 hours per day
Description: During 3 consecutive days

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Investigational devices must be used 8 hours per day
Description: During 3 consecutive days
Study: NCT05371080

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: HZ/su vaccine
Description: No study intervention is administered in this extension study. Participants received the HZ/su vaccine administered in the ZOSTER-049 (NCT02723773), ZOSTER-006 (NCT01165177) and ZOSTER-022 (NCT01165229) primary studies. In order to assess the persistence of immune responses, participants provide blood samples at Day 1 and yearly from Month 12 until Month 48 in the current ZOSTER-101 study, according to their study group assignment. In case of a suspected HZ case diagnosis in any of the participants, clinical specimens from HZ lesions (3 replicate samples, collected on the same day, per participant) are collected to confirm the diagnosis of HZ by Polymerase Chain Reaction (PCR)

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: HZ/su vaccine
Description: No study intervention is administered in this extension study. Participants received the HZ/su vaccine administered in the ZOSTER-049 (NCT02723773), ZOSTER-006 (NCT01165177) and ZOSTER-022 (NCT01165229) primary studies. In order to assess the persistence of immune responses, participants provide blood samples at Day 1 and yearly from Month 12 until Month 48 in the current ZOSTER-101 study, according to their study group assignment. In case of a suspected HZ case diagnosis in any of the participants, clinical specimens from HZ lesions (3 replicate samples, collected on the same day, per participant) are collected to confirm the diagnosis of HZ by Polymerase Chain Reaction (PCR)
Study: NCT05694832

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Expressive Writing
Description: Creative writing, discussion and social support, in a group setting via videoconference
Study: NCT04839471

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI-754091 plus afatinib
Description: Eligible patients will receive BI-754091 240 mg on D1, afatinib 30 mg/day on day 1 to 21 in a 3-week cycle.
Study: NCT06069141

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Benzathine Penicillin G
Description: Benzathine Penicillin G (2.4 MU intramuscularly once)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Benzathine Penicillin G
Description: Benzathine Penicillin G (2.4 MU intramuscularly once)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxycycline Capsule
Description: doxycycline (100 mg orally twice daily for 7 days)